SCHEMBL14035007

SCHEMBL14035007

Bc1ccc2nccc(Nc3cc(O)cc(OC)c3)c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAK O14976 13/20 0.54
RIPK2 O43353 11/20 0.54
COQ8A Q8NI60 10/20 0.54
NLK Q9UBE8 10/20 0.54
KDR P35968 1/20 0.52
RAF1 P04049 1/20 0.49
BRAF P15056 1/20 0.49
EPHB6 O15197 3/20 0.47
ABL1 P00519 3/20 0.47
ACVR1 Q04771 2/20 0.47
STK16 O75716 1/20 0.47
AAK1 Q2M2I8 1/20 0.47
HTT P42858 1/20 0.46
MAPKAPK2 P49137 1/20 0.46
LCK P06239 2/20 0.45
EPHA1 P21709 2/20 0.45
EPHA8 P29322 2/20 0.45
EGFR P00533 2/20 0.45
BMPR1B O00238 1/20 0.45
SRC P12931 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14035048 0.87 RIPK2 (0.56) GAKRIPK2COQ8ANLKKDR
SCHEMBL30880714 0.86 GAK (0.65) GAKRIPK2COQ8ANLKKDR
SCHEMBL30880678 0.86 GAK (0.65) GAKRIPK2COQ8ANLKKDR
SCHEMBL30880470 0.86 GAK (0.65) GAKRIPK2COQ8ANLKKDR
SCHEMBL2289246 0.86 GAK (0.65) GAKRIPK2COQ8ANLKKDR
Hydrochloric Acid SCHEMBL2291538 0.85 GAK (0.64) GAKRIPK2COQ8ANLKKDR
SCHEMBL30880543 0.84 HTT (0.66) GAKRIPK2COQ8ANLKKDR
SCHEMBL13768243 0.81 GAK (0.58) GAKRIPK2COQ8ANLKKDR
SCHEMBL2285466 0.79 GAK (0.48) GAKRIPK2COQ8ANLKKDR
SCHEMBL12414419 0.79 GAK (0.47) GAKRIPK2COQ8ANLKKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008141843-A1 NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-11-27 WO disclosed